Clinical Trials Logo

Hypocalcemia clinical trials

View clinical trials related to Hypocalcemia.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05953376 Not yet recruiting - Trauma Clinical Trials

Empiric Calcium in Massive Transfusion

Start date: January 2025
Phase: Phase 3
Study type: Interventional

Calcium helps blood to clot and thereby stop bleeding. Trauma patients who experience large volume blood loss often require blood transfusions and bleeding is the most common cause of death. The purpose of this study is to see if giving intravenous calcium immediately to patients who require large volume blood transfusion will decrease transfusion requirements, vasopressor use and mortality in bleeding trauma patients.

NCT ID: NCT05732883 Not yet recruiting - Hypocalcemia Clinical Trials

The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

Thyroidectomy is a standard procedure for benign and malignant pathologies of the thyroid gland. Each year, some 100 total thyroidectomies are performed in Kowloon East Cluster, Hospital Authority, Hong Kong. Total thyroidectomy is associated with voice dysfunction and temporary hypocalcaemia in up to 80% and 50%, respectively. Previous study from our institute showed a 3% rate of permanent vocal cord palsy and 16% of permanent hypoparathyroidism requiring calcium and/or vitamin D supplements. The use of dexamethasone has been studied in the past in total thyroidectomy patients and has been shown to be safe and effective in improving post-operative nausea and vomiting. No complications or drug related side effects were associated with a single dose of steroid. Recent studies have also shown that Dexamethasone is effective in improving voice outcome and hypocalcaemia in thyroidectomy patients. The investigators aim to study the effect of Dexamethasone in post-operative voice outcome and hypocalcaemia. Objective assessment of the vocal cords during phonation will be performed pre-operative and post-operatively. Serum Calcium level will be monitored.

NCT ID: NCT05684536 Not yet recruiting - Hypocalcemia Clinical Trials

Comparison of Liagure Safety in Thyroidectomy With Conventional Thyroidectomy

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

To compare intraoperative and postoperative complication rates in thyroidectomy between ligasure and traditional vascular ligation and clipping .

NCT ID: NCT05252884 Not yet recruiting - Thyroid Cancer Clinical Trials

Calcium+Calcitriol Versus PTH for the Prevention of Hypocalcemia in Thyroidectomy. Randomized Clinical Trial

Start date: March 30, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to compare the frequency of post-thyroidectomy symptomatic and biochemical hypocalcaemia between the strategy of routine prophylactic calcium + calcitriol vs the administration of calcium guided by PTH values.

NCT ID: NCT04465227 Not yet recruiting - Hypoparathyroidism Clinical Trials

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

Background: The Calcium-Sensing Receptor (CaSR) detects the amount of calcium in the blood and urine. Parathyroid hormone (PTH) helps keep blood calcium levels normal. When PTH and calcium blood levels are low, this is called hypoparathyroidism. People with changes in the CaSR have a type of hypoparathyroidism called ADH1. ADH1 is treated with calcium supplements and vitamin D. But these do not always work, and can cause problems like kidney stones. Researchers want to see if the drug CLTX-305 is a better treatment option. Objective: To see if CLTX-305 is safe and works in people with ADH1. Eligibility: People ages 16 and older with ADH1 Design: Participants will be screened with: Medical history Physical exam Kidney ultrasound: Participants will lie on a table while a wand is moved over their back. Bone density test: Participants will lie on a table while an X-ray machine moves around them. Blood, urine, and heart tests The study is split into 3 periods. Participants may take part in some or all periods. In Periods 1 and 2, participants will take CLTX-305 by mouth once or twice daily for up to 5 days. Participants will stay at the NIH for 7 days and 6 nights. In Period 3, participants will take CLTX-305 at home for 24 weeks. They will have 3 inpatient visits that last 1 2 days each. Screening tests will be repeated during the study. Blood and urine will be collected often. Participants dose of calcium and vitamin D may be changed. They may be asked to stop taking other medicines or change the dose.

NCT ID: NCT04304573 Not yet recruiting - Clinical trials for Postoperative Complications

Is Correcting Total Serum Calcium Levels Important After Thyroidectomy

Start date: June 9, 2020
Phase:
Study type: Observational

This study is designed as a prospective non-randomized longitudinal single- center cohort study to evaluate the importance of correcting total serum calcium levels. It will enroll around 100 patients undergoing total thyroidectomy with data being collected from March 2020 up to August 2020. The aim of this study is to determine whether total serum calcium level should be corrected for serum albumin in assessing symptomatic hypocalcemia after total thyroidectomy and which variable (total serum calcium, ionized calcium, corrected serum calcium for albumin with Payne's formula or early PTH) is the most valuable predictor of symptomatic hypocalcemia after total thyroidectomy.

NCT ID: NCT04094493 Not yet recruiting - Thyroid Diseases Clinical Trials

Vit D Role in Post Thyroidectomy Hypocalcemia

Start date: October 1, 2019
Phase: Early Phase 1
Study type: Interventional

Hypocalcemia after total thyroidectomy is usually transient but it is of main concern as it requires either prolonged stay in the hospital or readmission. During the first 24 hours bleeding is the main complication, but from the second day to six months, transient hypocalcemia is of main concern. Hypocalcemia can be evaluated symptomatically as well as from laboratory testing. Signs and symptoms of hypocalcemia include numbness, tingling, and carpopedal spasm. Preoperative vitamin D prevents postoperative transient hypocalcemia after thyroidectomy .

NCT ID: NCT03685877 Not yet recruiting - Hypocalcemia Clinical Trials

Hypocalcemia in Infants and Children

Start date: March 30, 2019
Phase:
Study type: Observational

Hypocalcemia is defined as reduction in the level of the ionized calcium in the blood to less than 0.95 mmole/ litre. In some cases it is associated with symptoms such as neuromuscular impairment in the form of convulsions ,carpopedal spasm,parathesia ,laryngiospasm ,stridor……etc .Calcium circulates in blood stream in three fractions :protein bound to calcium,primarly to albumen(40%) and in 50% of the cases calcium is present in the ionized state which is physiologically active (Dias ,c et a l, 2013) . Symptomatizing hypocalcemia may occur in cases of vitamin D deficiency rickets (nutritional deficiency in infants less than two years ) .It may also occur in vitamin D resistant rickets e.g renal rickets because of failure of the kidney to synthesize 1-OH cholecalciferol of the 1-25 di-OH cholecalciferol (the active form of vitamin D).

NCT ID: NCT03063060 Not yet recruiting - Clinical trials for Vitamin D Deficiency

The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy

Start date: March 1, 2017
Phase: N/A
Study type: Observational

Post-operative hypocalcaemia following total thyroidectomy is a well-known complication and becoming a major area of research. Many factors are assumed to increase the incidence of post-thyroidectomy hypocalcaemia, but the impact of vitamin D deficiency remains uncertain. Since results so far were inconclusive, the goal in this study is to significantly determine the relation between those two factors. This study is the first to deal with this issue through patients who underwent total thyroidectomy that was performed by the same surgeon and the same surgical technique. A retrospective evaluation study of patients who underwent total thyroidectomy at the head and neck unit of the Otorhinolaryngology department at our institution between January 2013 and October 2016. A total number of 60 patients underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels. Pre-operative vitamin D and PTH levels were checked within a maximum of one month duration before surgery. All patients were operated by the same surgeon -Dr. Galit Avior-, with the same surgical technique. The study involves access to the patients files and admission reports. In addition the investigators would like to be able to call the patients in order to ask them whether Vitamin D deficiency was corrected or not before their surgery, and If it was corrected then when exactly.

NCT ID: NCT01021280 Not yet recruiting - Hypocalcemia Clinical Trials

Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome

Start date: January 2013
Phase: N/A
Study type: Observational

Parathyroid hormone (PTH) gland calcium sensing receptor (CASR) regulates PTH secretion. CASR is also expressed in nephron thick ascending limb (TAL). Bartter syndrome (BS), a normotensive hypokalemic tubulopathy, may be due to mutations in different TAL channels, including the potassium channel ROMK. Mutations in CASR may also cause BS through its effects on ROMK function. However, it is unknown whether ROMK mutations exert any effects on CASR function and PTH physiology. Preliminary data from our center shows that PTH levels were specifically elevated in type II (where ROMK is mutated) and not in type IV (where another gene, Barttin is defective) BS, without a common explanation. We assume that the mutation in ROMK may cause a dysregulation of PTH secretion via possible interaction with CASR. The purpose of this study is: to investigate the PT-gland function and regulation in BS. Methods: Patients with BS type II and IV and normal controls will undergo a standard protocol of controlled ionic hypo- and hypercalcemia, during which PTH secretion, phosphate balance and calcium excretion will be followed. Calcium Vs PTH response curves will be generated and compared. Expected impact and benefit: the results of this study will help understand the mechanisms of PTH regulation beyond CASR.